Table 3. Summary of salvage BT case series studies in radio-recurrent prostate cancer.
| Study | Study design | No. of patients and BT type | Median follow-up duration (months) | BCR-free survival (%) | MFS (%) | CSS (%) | OS (%) | Treatment toxicity |
|---|---|---|---|---|---|---|---|---|
| Smith et al., 2021 (34) | Multi-center, retrospective | 108 LDR | 75.6 | 63.1 (5-yr) | NR | 90.5 (5-yr) | 80.9 (5-yr) | Gr 3: 16.7% (GU 15.7%, GI 2.8%) |
| 52.0 (10-yr) | 77.8 (10-yr) | 56.7 (10-yr) | ||||||
| Crook et al., 2019 and 2022 (35,36) | Multi-center, prospective | 100 LDR | 80.4 | 54 (10-yr) | 81 (10-yr) | NR | 70 (10-yr) | NR |
| Kunogi et al., 2016 (37) | Single-center, retrospective | 12 LDR (focal) | 56 | 78 (4-yr) | NR | NR | NR | No Gr 3 GU/GI toxicity |
| Peters et al., 2014 (38) | Single-center, retrospective | 20 LDR (focal) | 36 | 60 (3-yr) | NR | NR | NR | 1 Gr 3 GU toxicity |
| No greater than Gr 4 toxicity | ||||||||
| Chen et al., 2013 (39) | Single-center, retrospective | 52 HDR | 59.6 | 51 (5-yr) | NR | NR | 92 (5-yr) | 2% acute and 2% late Gr 3 GU toxicities/4% Gr 2 GI late events |
| Wu et al., 2021 (40) | Single-center, retrospective | 129 HDR | 68 | 85 (3-yr) | NR | NR | NR | 19 (15%) strictures requiring dilation |
| 71 (5-yr) | ||||||||
| Wojcieszek et al., 2016 (41) | Single-center, retrospective | 83 HDR | 41 | 76 (3-yr) | NR | NR | 93 (3-yr) | 13% Gr 3 GU toxicity with no Gr 2 or 3 GI toxicities |
| 67 (5-yr) | 86 (5-yr) | |||||||
| Henríquez López et al., 2019 (42) | Multi-center, retrospective | 44 LDR | 52 | Overall: 71 (5-yr) | NR | LDR: 96.5 (5-yr) | NR | 23.5% Gr 3 or more toxicity |
| 75 HDR | LDR: 79 (5-yr) | HDR: 93 (5-yr) | ||||||
| HDR: 65 (5-yr) | ||||||||
| Murgic et al., 2018 (43) | Single-center, prospective | 15 HDR (focal) | 36 | 61 (3-yr) | NR | NR | NR | Only 1 Gr 3 GU toxicity |
| Maenhout et al., 2017 (44) | Single-center, retrospective | 17 HDR (focal) | 10 | Only 1 patient showed a BCR | NR | NR | NR | 1 Gr 3 urethral stricture at 2 years after treatment |
| van Son et al., 2020 (45) | Single-center, retrospective | 50 HDR (focal) | 31 | 51 (2.5-yr) | 75 (2.5-yr) | NR | 98 (2.5-yr) | 2% Gr 3 GU toxicity, no Gr 3 GI toxicity |
BT, brachytherapy; BCR, biochemical recurrence; MFS, metastasis-free survival; CSS, cancer-specific survival; OS, overall survival; LDR, low-dose-rate; yr, year; NR, not reported; Gr, grade; GU, genitourinary; GI, gastrointestinal; HDR, high-dose-rate.